Literature DB >> 26666764

Associations between allergic conditions and pediatric brain tumors in Neurofibromatosis type 1.

Bree Porcelli1, Nancy L Zoellner2, Salmafatima S Abadin2, David H Gutmann1, Kimberly J Johnson3.   

Abstract

Individuals with Neurofibromatosis type 1 (NF1) are at increased risk for pediatric brain tumors (PBTs), especially optic gliomas; however, factors influencing their development are largely unknown. Extensive research suggests that allergic conditions protect against brain tumors, particularly gliomas in individuals without NF1. In this large cross-sectional study, we employed two different data sources to evaluate evidence for the hypothesis that allergic conditions (allergies, asthma, and eczema) may protect against PBT development in individuals with NF1. We used self- and parent/legal guardian reported questionnaire data from participants in the NF1 Patient Registry Initiative (NPRI, n = 1660) born from 1933 to 2014 to ascertain allergic condition and PBT diagnosis histories. Medical records (MRs) of 629 NF1 patients at a large medical center born from 1930 to 2012 were also reviewed for PBT and allergic condition diagnoses to evaluate additional evidence for our hypothesis. We used logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between allergic condition diagnoses and PBTs. Both data sources provided limited to no support for a protective effect of allergies or eczema on PBT development. Non-significant inverse associations between asthma and PBTs were observed (NPRI: OR = 0.80, 95% CI 0.55-1.17; MR: OR = 0.71, 95% CI 0.40-1.28) with stronger associations for optic gliomas specifically. Additionally, a significant inverse association was observed in an NPRI subgroup analysis where the reported asthma diagnosis age was younger than the reported PBT diagnosis age (OR = 0.57; 95% CI 0.36-0.89). Our study supports the hypothesis that asthma protects against PBT development in NF1.

Entities:  

Keywords:  Allergies; Asthma; Brain tumors; Neurofibromatosis type 1; Optic pathway gliomas

Mesh:

Year:  2016        PMID: 26666764      PMCID: PMC5080205          DOI: 10.1007/s10689-015-9855-3

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  32 in total

1.  Allergic conditions reduce the risk of glioma: a meta-analysis based on 128,936 subjects.

Authors:  Hongyu Zhao; Weisong Cai; Shitao Su; Debao Zhi; Jie Lu; Shuo Liu
Journal:  Tumour Biol       Date:  2013-12-18

Review 2.  Neurofibromatosis 1.

Authors:  Timothy M Lynch; David H Gutmann
Journal:  Neurol Clin       Date:  2002-08       Impact factor: 3.806

3.  Validity of participant-reported diagnoses in an online patient registry: a report from the NF1 Patient Registry Initiative.

Authors:  Evelyn K Sharkey; Nancy L Zoellner; Salmafatima Abadin; David H Gutmann; Kimberly J Johnson
Journal:  Contemp Clin Trials       Date:  2014-12-19       Impact factor: 2.226

4.  Racial/Ethnic Differences in Pediatric Brain Tumor Diagnoses in Patients with Neurofibromatosis Type 1.

Authors:  Salmafatima S Abadin; Nancy L Zoellner; Melody Schaeffer; Bree Porcelli; David H Gutmann; Kimberly J Johnson
Journal:  J Pediatr       Date:  2015-05-28       Impact factor: 4.406

Review 5.  Epidemiology of neurofibromatosis type 1.

Authors:  J M Friedman
Journal:  Am J Med Genet       Date:  1999-03-26

6.  Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation.

Authors:  Girish C Daginakatte; Scott M Gianino; Nina W Zhao; Alexander S Parsadanian; David H Gutmann
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

7.  Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation.

Authors:  Winnie W Pong; Samantha B Higer; Scott M Gianino; Ryan J Emnett; David H Gutmann
Journal:  Ann Neurol       Date:  2013-02-19       Impact factor: 10.422

8.  Allergy and brain tumors in the INTERPHONE study: pooled results from Australia, Canada, France, Israel, and New Zealand.

Authors:  Michelle C Turner; Daniel Krewski; Bruce K Armstrong; Angela Chetrit; Graham G Giles; Martine Hours; Mary L McBride; Marie-Élise Parent; Siegal Sadetzki; Jack Siemiatycki; Alistair Woodward; Elisabeth Cardis
Journal:  Cancer Causes Control       Date:  2013-02-27       Impact factor: 2.506

9.  Epilepsy in individuals with neurofibromatosis type 1.

Authors:  Adam P Ostendorf; David H Gutmann; Judith L Z Weisenberg
Journal:  Epilepsia       Date:  2013-08-29       Impact factor: 5.864

10.  Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome.

Authors:  Allison King; Robert Listernick; Joel Charrow; Linda Piersall; David H Gutmann
Journal:  Am J Med Genet A       Date:  2003-10-01       Impact factor: 2.802

View more
  5 in total

Review 1.  Microglia as Dynamic Cellular Mediators of Brain Function.

Authors:  Elizabeth C Wright-Jin; David H Gutmann
Journal:  Trends Mol Med       Date:  2019-10-06       Impact factor: 11.951

Review 2.  Optic Pathway Gliomas in Neurofibromatosis Type 1.

Authors:  Cynthia J Campen; David H Gutmann
Journal:  J Child Neurol       Date:  2018-01       Impact factor: 1.987

Review 3.  T lymphocytes as dynamic regulators of glioma pathobiology.

Authors:  Elizabeth C Cordell; Mahmoud S Alghamri; Maria G Castro; David H Gutmann
Journal:  Neuro Oncol       Date:  2022-10-03       Impact factor: 13.029

Review 4.  Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade Glioma.

Authors:  Cora A Ricker; Yuan Pan; David H Gutmann; Charles Keller
Journal:  Front Oncol       Date:  2016-12-20       Impact factor: 6.244

5.  Asthma reduces glioma formation by T cell decorin-mediated inhibition of microglia.

Authors:  Jit Chatterjee; Shilpa Sanapala; Olivia Cobb; Alice Bewley; Andrea K Goldstein; Elizabeth Cordell; Xia Ge; Joel R Garbow; Michael J Holtzman; David H Gutmann
Journal:  Nat Commun       Date:  2021-12-08       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.